scholarly journals Sentinel node biopsy in breast cancer patients undergoing induction chemotherapy should be performed prior to chemotherapy

2017 ◽  
Vol 67 (4) ◽  
pp. 267-269
Author(s):  
Janusz Piekarski
Keyword(s):  
Breast Cancer ◽  
Sentinel Node ◽  
Cancer Patients ◽  
Sentinel Node Biopsy ◽  
Induction Chemotherapy ◽  
Breast Cancer Patients ◽  
Node Biopsy

scholarly journals Sentinel Node Biopsy Guided by Indocyanin Green Dye in Breast Cancer Patients

1999 ◽  
Vol 29 (12) ◽  
pp. 604-607 ◽  
Author(s):  
K. Motomura ◽  
H. Inaji ◽  
Y. Komoike ◽  
T. Kasugai ◽  
S. Noguchi ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Sentinel Node ◽  
Cancer Patients ◽  
Sentinel Node Biopsy ◽  
Breast Cancer Patients ◽  
Node Biopsy

scholarly journals Added value of blue dye injection in sentinel node biopsy of breast cancer patients: Do all patients need blue dye?

2014 ◽  
Vol 12 (4) ◽  
pp. 325-328 ◽  
Author(s):  
Ramin Sadeghi ◽  
Ghazaleh Alesheikh ◽  
Seyed Rasoul Zakavi ◽  
Asiehsadat Fattahi ◽  
Abbas Abdollahi ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Sentinel Node ◽  
Cancer Patients ◽  
Sentinel Node Biopsy ◽  
Added Value ◽  
Blue Dye ◽  
Breast Cancer Patients ◽  
Node Biopsy

scholarly journals Platelet-Rich Plasma (PRP) in Breast Cancer Patients: An Application Analysis of 163 Sentinel Lymph Node Biopsies

2020 ◽  
Vol 2020 ◽  
pp. 1-7
Author(s):  
C. Eichler ◽  
C. Baucks ◽  
J. Üner ◽  
C. Pahmeyer ◽  
D. Ratiu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Sentinel Node ◽  
Cancer Patients ◽  
Sentinel Node Biopsy ◽  
Platelet Rich Plasma ◽  
Distant Metastases ◽  
Complication Rates ◽  
Breast Cancer Patients ◽  
Node Biopsy

Introduction. Literature shows platelet-rich plasma (PRP) to improve overall outcomes in orthopedics, dermatology, ophthalmology, gynecology, and plastic surgery. Data on oncological patients is very limited. Only one publication is available on PRP in breast cancer patients. This work evaluated PRP in sentinel node biopsy procedures for breast cancer patients in terms of complication rates and oncological short-term follow-up. Methods. The evaluated PRP was ACP®, i.e., autologous conditioned plasma by Arthrex®. Between 2015 and 2018, 163 patients were offered to receive an ACP®/PRP injection in their lymph node biopsy site. Recruitment resulted in an approximate one-to-one ratio for analysis. Endpoints were major (revision) and minor (seroma, hematoma, and infection) complications rates as well as distant metastases, local recurrence, and overall survival. Median follow-up was 30 months. Results. Complication rates and oncological follow-up showed PRP to be applicable to use in a sentinel node biopsy scenario in breast cancer patients. There were 0 revisions in the ACP®/PRP group and 1.2% revisions in the control group (not significant). Oncological follow-up showed zero (0) distant metastases and local recurrences as well as a 100% 30-month overall survival. Conclusions. This is the first analysis of ACP®/PRP used in breast cancer patients in a sentinel node biopsy setting worldwide. PRP does not seem to increase rates of local recurrence within this 30-month follow-up time frame. Also, trend towards decreasing complication rates could be shown.

Sign in / Sign up

Export Citation Format

Share Document